A French biotech company located in Montpellier has patented vectors allowing a smooth engineering of therapeutic antibodies thus leading to an improvement of their biological properties. The technology improves the degradation of the antigen and increases the efficacy of the antibody. The higher efficacy can allow the decreasing of side effects for the patient and reduce the doses of the therapeutic treatment. Moreover, this new class of engineered antibodies can be patented for therapeutic use.
The company has a deep knowledge in:
- Synthesis of glycovectors and protein engineering,
- Preclinical proof-of-concept in cell cultures and murine models,
- Patent delivery and medical drug designation.
Capacity of production :
- vectors > 10 kg under Good Manufacturing Practices (GMP) standards
Thanks to its home skills and equipment and to the surrounding scientific platforms, the company benefits of all the facilities to perform biological, biochemical, analytical and chemical experiments. The company searches a partner who already produces a therapeutic antibody whose mechanism of action concerns the degradation of the antigen. The grafting of the vectors on antibodies will increase their therapeutic efficacy and will generate Intellectual Property.
This concept could be applied to immunotherapies in the area of oncology, inflammatory or auto-immune diseases or rare diseases. The company wishes to establish suitable and long-term business partnerships through technical cooperation agreement, research or license agreement.